文献速递造血干细胞移植与细胞治疗

稳健的质量基础设施是安全有效递送免疫效应细胞的关键:FACT 发现如何提供帮助

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help.
PubMed 文献 · Blood Adv · 2024-01-01

免疫效应细胞(IEC)涵盖多种免疫细胞,可用于恶性及非恶性疾病。随着 IEC 作为研究性及商业化产品使用增长,医疗机构需建立工作流程以安全实施该疗法。FACT 已建立细胞治疗标准及项目框架,本文概述 IEC 项目发展现状、认证及挑战解决方案。

要点

  • 免疫效应细胞(IEC)包括嵌合抗原受体(CAR)-T 细胞等,靶点、疾病、来源及毒性多样。
  • FACT 已建立涵盖造血干细胞移植(HCT)及 IEC 产品的细胞治疗标准。
  • FACT 建立项目框架以改善 IEC 治疗递送,应对机构带宽与基础设施挑战。

核心结论

  • FACT 已建立项目框架以改善免疫效应细胞(IEC)治疗的递送,并概述了项目发展、认证及挑战的解决方案。

研究设计与样本

  • 本文为综述,概述免疫效应细胞(IEC)项目发展现状、认证及挑战解决方案。

主要发现

  • 免疫效应细胞(IEC)涵盖多种免疫细胞,可调节恶性及非恶性疾病状态。
  • IEC 作为研究性及商业化产品使用增长,要求医疗机构建立工作流程以安全实施和递送该疗法。
  • IEC 治疗的复杂性包括靶点、疾病、来源多样及患者治疗后独特毒性。
  • FACT 已建立细胞治疗标准超过 25 年,最初用于造血干细胞移植(HCT),近期扩展至嵌合抗原受体(CAR)-T 细胞等 IEC 产品。
  • IEC 治疗已挑战提供该疗法机构的带宽和基础设施,FACT 为此建立项目框架。

关键数值与推荐

  • FACT 已建立细胞治疗使用标准超过 25 年。
  • FACT 标准最初涵盖造血干细胞移植(HCT),近期扩展至嵌合抗原受体(CAR)-T 细胞等 IEC 产品。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune effector cells (IECs) include a broad range of immune cells capable of modulating several disease states, including malignant and nonmalignant conditions. The growth in the use of IECs as both investigational and commercially available products requires medical institutions to develop workflows/processes to safely implement and deliver transformative therapy. Adding to the complexity of this therapy are the variety of targets, diseases, sources, and unique toxicities that a patient experiences following IEC therapy. For over 25 years, the Foundation for the Accreditation of Cellular Therapy (FACT) has established a standard for the use of cellular therapy, initially with hematopoietic cell transplantation (HCT), and more recently, with the development of standards to encompass IEC products such as chimeric antigen receptor (CAR)-T cells. To date, IEC therapy has challenged the bandwidth and infrastructure of the institutions offering this therapy. To address these challenges, FACT has established a programmatic framework to improve the delivery of IEC therapy. In this study, we outline the current state of IEC program development, accreditation, and solutions to the challenges that programs face as they expand their application to novel IEC therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Curran KJ, Nikiforow S, Bachier C, et al. A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help. Blood Adv. 2024. PMID: 37467016. doi:10.1182/bloodadvances.2023010401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。